Bedel Financial Consulting’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $761K | Sell |
31,588
-1,789
| -5% | -$46.8K | 0.07% | 137 |
|
|
2026
Q1 | $937K | Sell |
33,377
-137
| -0.4% | -$3.65K | 0.11% | 110 |
|
|
2025
Q4 | $835K | Sell |
33,514
-1,534
| -4% | -$38.7K | 0.09% | 120 |
|
|
2025
Q3 | $893K | Sell |
35,048
-1,421
| -4% | -$35.1K | 0.11% | 107 |
|
|
2025
Q2 | $884K | Sell |
36,469
-305
| -0.8% | -$7.11K | 0.12% | 101 |
|
|
2025
Q1 | $841K | Buy |
36,774
+1,950
| +6% | +$51K | 0.12% | 99 |
|
|
2024
Q4 | $921K | Buy |
34,824
+5,329
| +18% | +$145K | 0.13% | 94 |
|
|
2024
Q3 | $854K | Buy |
29,495
+1,522
| +5% | +$44.4K | 0.12% | 94 |
|
|
2024
Q2 | $783K | Buy |
27,973
+70
| +0.3% | +$1.93K | 0.11% | 94 |
|
|
2024
Q1 | $774K | Buy |
27,903
+29
| +0.1% | +$805 | 0.12% | 91 |
|
|
2023
Q4 | $802K | Sell |
27,874
-1,601
| -5% | -$48.4K | 0.15% | 85 |
|
|
2023
Q3 | $978K | Sell |
29,475
-264
| -0.9% | -$9.34K | 0.2% | 67 |
|
|
2023
Q2 | $1.09M | Buy |
29,739
+1,571
| +6% | +$61.1K | 0.23% | 65 |
|
|
2023
Q1 | $1.15M | Sell |
28,168
-438
| -2% | -$18.9K | 0.28% | 54 |
|
|
2022
Q4 | $1.47M | Buy |
28,606
+1,604
| +6% | +$76.9K | 0.36% | 39 |
|
|
2022
Q3 | $1.27M | Buy |
27,002
+1,856
| +7% | +$90.2K | 0.34% | 44 |
|
|
2022
Q2 | $1.32M | Buy |
25,146
+2,346
| +10% | +$120K | 0.39% | 35 |
|
|
2022
Q1 | $1.18M | Buy |
22,800
+776
| +4% | +$40.3K | 0.37% | 37 |
|
|
2021
Q4 | $1.3M | Buy |
22,024
+212
| +1% | +$10.5K | 0.4% | 37 |
|
|
2021
Q3 | $938K | Sell |
21,812
-122
| -0.6% | -$5.41K | 0.32% | 46 |
|
|
2021
Q2 | $859K | Buy |
21,934
+1,377
| +7% | +$53.5K | 0.3% | 49 |
|
|
2021
Q1 | $745K | Buy |
20,557
+2,737
| +15% | +$97.2K | 0.29% | 52 |
|
|
2020
Q4 | $656K | Sell |
17,820
-788
| -4% | -$28.9K | 0.29% | 51 |
|
|
2020
Q3 | $648K | Buy |
18,608
+105
| +0.6% | +$3.68K | 0.32% | 48 |
|
|
2020
Q2 | $574K | Sell |
18,503
-1,330
| -7% | -$45.2K | 0.31% | 50 |
|
|
2020
Q1 | $614K | Buy |
19,833
+403
| +2% | +$13.7K | 0.41% | 36 |
|
|
2019
Q4 | $722K | Sell |
19,430
-4,732
| -20% | -$169K | 0.41% | 40 |
|
|
2019
Q3 | $824K | Buy |
24,162
+154
| +0.6% | +$5.6K | 0.5% | 31 |
|
|
2019
Q2 | $987K | Sell |
24,008
-424
| -2% | -$16.8K | 0.6% | 27 |
|
|
2019
Q1 | $984K | Buy |
24,432
+2
| +0% | +$80 | 0.63% | 28 |
|
|
2018
Q4 | $1.01M | Sell |
24,430
-718
| -3% | -$29.8K | 0.73% | 23 |
|
|
2018
Q3 | $1.05M | Buy |
25,148
+689
| +3% | +$26.5K | 0.7% | 24 |
|
|
2018
Q2 | $842K | Sell |
24,459
-1,014
| -4% | -$34.7K | 0.62% | 30 |
|
|
2018
Q1 | $858K | Buy |
25,473
+3
| +0% | +$103 | 0.65% | 28 |
|
|
2017
Q4 | $875K | Buy |
+25,470
| New | +$868K | 0.79% | 26 |
|
Other funds holding PFE
Bedel Financial Consulting's PFE Position: Q2 2026 in Review
Bedel Financial Consulting reduced its Pfizer (PFE) stake by 5.4% in Q2 2026, selling an estimated $46.8K and leaving 31,588 shares worth $761K. The position accounts for 0.07% of the portfolio, ranked #137.
Bedel Financial Consulting first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.47M in Q4 2022. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Bedel Financial Consulting held 31,588 shares of Pfizer worth $761K as of Q2 2026.
- Bedel Financial Consulting sold 1,789 Pfizer shares in Q2 2026, an estimated $46.8K.
- Pfizer made up 0.07% of Bedel Financial Consulting's portfolio in Q2 2026, its #137 holding.
- Bedel Financial Consulting first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Bedel Financial Consulting's Pfizer position peaked at $1.47M in Q4 2022.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Bedel Financial Consulting's 13F filing for Q2 2026, filed 29 Jul 2026.